cGMP manufacturing for (pre-)clinical trials ... - Eurogentec
cGMP manufacturing for (pre-)clinical trials ... - Eurogentec
cGMP manufacturing for (pre-)clinical trials ... - Eurogentec
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Therapeutic<br />
Oligonucleotides<br />
<strong>cGMP</strong> <strong>manufacturing</strong><br />
<strong>for</strong> (<strong>pre</strong>-)<strong>clinical</strong> <strong>trials</strong>
New from <strong>Eurogentec</strong>: Therapeutic Oligonucleotides<br />
Oligonucleotide-based drugs are now rapidly establishing themselves as important tools<br />
in both research and treatment of genetic disorders. Recent knowledge about RNA<br />
interference has boosted interest in this field. An increasing number of oligonucleotidebased<br />
pharmaceutical products are now in in various stages of <strong>clinical</strong> development <strong>for</strong><br />
the treatment of life-threatening so far incurable diseases. As a result, the production of<br />
synthetic oligonucleotides has become increasingly important, with applications in<br />
antisense-, aptamer-, immunostimulatory CpG molecule- and RNAi-related therapeutics.<br />
In response to this development, <strong>Eurogentec</strong> Biologics, leader in GMP <strong>manufacturing</strong> of<br />
biopharmaceuticals and <strong>Eurogentec</strong> Genomics, expert in oligonucleotide synthesis and<br />
purification, have joint <strong>for</strong>ces to offer a new service: <strong>cGMP</strong> <strong>manufacturing</strong> of<br />
oligonucleotides <strong>for</strong> therapeutic use.<br />
Global solution in one company: from target discovery to<br />
<strong>clinical</strong> <strong>trials</strong><br />
<strong>Eurogentec</strong>’s approach in building a new team with synergistic expertise has resulted in a<br />
unique service that helps minimize the risks attached to outsourcing <strong>manufacturing</strong> in<br />
oligonucleotide drug development. By offering small-scale non-<strong>cGMP</strong> oligonucleotides <strong>for</strong><br />
target discovery and <strong>pre</strong>-<strong>clinical</strong> toxicology studies (typically less than 1 gram) and<br />
mid-scale <strong>cGMP</strong> oligonucleotides <strong>for</strong> human <strong>clinical</strong> <strong>trials</strong> (up to 10 gram), we deliver an<br />
integrated <strong>manufacturing</strong> program that enables seamless transition from target discovery<br />
and <strong>pre</strong>-<strong>clinical</strong> studies to <strong>clinical</strong> <strong>trials</strong>.<br />
� Expertise to produce complex and modified oligonucleotides (siRNA, LNA, 2’OMe…).<br />
� Expert advice on oligonucleotide design and delivery systems.<br />
� Dedicated <strong>cGMP</strong> facilities <strong>for</strong> RNA and DNA production.<br />
� Capacities from milligrams to 10 gram and beyond.<br />
� Lab and industrial scale purification systems.<br />
� Ultra filtration and freeze drying.<br />
� Clean rooms <strong>for</strong> purification and isolation.<br />
� Full range of QC release testing specific to oligonucleotides.<br />
� Biodistribution and design services<br />
About <strong>Eurogentec</strong> Biologics<br />
The Biologics Division of <strong>Eurogentec</strong> is a leading contract manufacturer of<br />
biopharmaceuticals <strong>for</strong> <strong>clinical</strong> <strong>trials</strong> and market supply. We offer cell banking, process<br />
and analytical development and production of bacterial vaccines, recombinant or natural<br />
proteins and plasmid DNA according to current GMPs of European and US regulatory<br />
authorities. To date, <strong>Eurogentec</strong> Biologics has manufactured more than 270 <strong>clinical</strong><br />
batches of over 60 different drug substances. For the past 12 years, we have successfully<br />
served small start-ups and large pharmaceutical companies in Europe and North America<br />
and are committed to expand our services worldwide.<br />
About <strong>Eurogentec</strong> Genomics<br />
With over 20 years of experience in oligonucleotide synthesis, <strong>Eurogentec</strong> has grown into<br />
a leading provider <strong>for</strong> genomic research as well as DNA- and RNA-based diagnostic<br />
testing. <strong>Eurogentec</strong> maintains a proven track record of <strong>manufacturing</strong> the widest range<br />
of oligonucleotide modifications in the industry. Being a healthy and professional<br />
company, we are able to offer reliable, flexible and cost-effective solutions <strong>for</strong> research,<br />
R&D and <strong>clinical</strong> use of oligonucleotides.
<strong>Eurogentec</strong>, your oligonucleotide partner of<br />
choice in drug development.<br />
For inquiries, please contact the EUROGENTEC Diagnostic Oligonucleotide Team:<br />
IND-THERAPOLIGO-0507-V3<br />
Customers in Europe and USA:<br />
Tel.: + 32 (0)4 372 7437 (Muriel Craynest, Ph.D.)<br />
Tel.: + 32 (0)4 372 7635 (Peter Haima, Ph.D.)<br />
therapeutic.oligo@eurogentec.com<br />
Customers in Asia:<br />
Tel.: + 81 (0)76 411 02 77 (Japan)<br />
info@n-egt.com<br />
Tel.: + 65 (0)6778 9388 (Singapore)<br />
therapeutic.oligo@eurogentec.com